Search

Displaying results 1261 - 1270 of 7604 in total
  1. Drug

    Lamotrigine

    go.drugbank.com/drugs/DB00555
    ApprovedInvestigational

    Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 countries. … While it is indicated for epilepsy and bipolar disorders, there is evidence that lamotrigine could have some clinical efficacy in certain neuropathic pain states.[A849,A850]

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesProducts: LAMOTRIGINA POR 200 MG
  2. Indication

    Accelerated Phase Chronic Myelogenous Leukemia (CML)

    go.drugbank.com/conditions/DBCOND0121922
    Drugs: Bosutinib · Dasatinib · Imatinib · Nilotinib · Ponatinib
    Synonyms: Chronic myelogenous leukemia, no International Classification of Diseases for Oncology subtype
  3. Indication

    Classical Hodgkin's Lymphoma

    go.drugbank.com/conditions/DBCOND0113588
    Drugs: Brentuximab vedotin · Nivolumab
    Synonyms: Hodgkin lymphoma, no International Classification of Diseases for Oncology subtype
  4. Drug

    Perhexiline

    go.drugbank.com/drugs/DB01074
    Approved

    Perhexiline is a coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.

  5. Drug

    Mifamurtide

    go.drugbank.com/drugs/DB13615
    ApprovedInvestigational

    In the US, it is currently under investigation that holds orphan drug status for the treatment of osteosarcoma [A31746]. … Mifamurtide is marketed in Europe as Mepact for intravenous infusion.

  6. Drug

    Cupric sulfate

    go.drugbank.com/drugs/DB06778
    Approved

    The anhydrous salt is created by heating the hydrate to 150 °C (300 °F). Cupric sulfate is used primarily for agricultural purposes, as a pesticide, germicide, feed additive, and soil additive. … Cupric sulfate is a salt created by treating cupric oxide with sulfuric acid.

    Mixtures: Pnv-VP-UCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Belzutifan

    go.drugbank.com/drugs/DB15463
    ApprovedInvestigational

    [L36000] It was later approved for the treatment of locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in patients aged 12 years and older.[L49271] … Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021.

  8. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    [L5956, L5959] At the same time, the FDA also approved the therascreen FGFR RGQ RT-PCR Kit (Qiagen) for utilization as a companion diagnostic with erdafitinib for selecting patients for the indicated therapy … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

  9. Drug

    Sepiapterin

    go.drugbank.com/drugs/DB16326
    ApprovedInvestigational

    [L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria.

  10. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    [L48701] It was also later approved by the EMA on December 4, 2023, as an add-on treatment for the same condition.[L49131] In July 2024, it was approved by Health Canada for the same indication. … [A261841] On October 17, 2023, zilucoplan gained its first FDA approval for the treatment of generalized myasthenia gravis.